Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

News Conference News EuroPCR 2025

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Yael L. Maxwell

June 02, 2025

News Conference News EuroPCR 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

L.A. McKeown

May 30, 2025

News Conference News EuroPCR 2025

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

Michael O'Riordan

May 29, 2025

News Conference News EuroPCR 2025

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

Yael L. Maxwell

May 23, 2025

News Conference News EuroPCR 2025

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

L.A. McKeown

May 22, 2025

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Daily News

The ‘Smoker’s Paradox’ Takes a New Hit From Long-term Analysis

Yael L. Maxwell

March 24, 2025

News Daily News

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

Yael L. Maxwell

March 13, 2025

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Daily News

Early Invasive Treatment May Help Highest-Risk Women With NSTE ACS

Yael L. Maxwell

March 10, 2025

News Daily News

Can’t Exercise for a Cardiac Stress Test? That’s a Bad Sign

Todd Neale

February 25, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

Advertisement

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

The ‘Smoker’s Paradox’ Takes a New Hit From Long-term Analysis

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Early Invasive Treatment May Help Highest-Risk Women With NSTE ACS

Can’t Exercise for a Cardiac Stress Test? That’s a Bad Sign

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content